Appili, DoD Expand Vaccine Deal

Armando Balboni, the CEO of Halifax drug discovery company Appili Therapeutics is leaving his role to become the company’s chairman and rejoin the United States military as Director of the Life Sciences Research Center at the United States Air Force academy. He will also oversea a deal that will see Appili produce a tularemia vaccine for the Department of Defence.
The deal, worth US$14 million